LOAMU
VRTX icon

Lombard Odier Asset Management (USA)’s Vertex Pharmaceuticals VRTX Stock Holding History

Lombard Odier Asset Management (USA)’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-50,000
Closed -$9.07M – 428
2021
Q3 		$9.07M Hold
50,000
– – 0.4% 45
2021
Q2 		$10.1M Buy
+50,000
New +$10.5M 0.4% 50

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Lombard Odier Asset Management (USA)'s VRTX Position: Q4 2025 in Review

Lombard Odier Asset Management (USA) sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 651 shares — an estimated $255K sold.

Lombard Odier Asset Management (USA) first reported a position in VRTX in Q1 2020 and held it in 5 quarters. The position peaked at $7.56M in Q3 2021. 1,668 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

  • Lombard Odier Asset Management (USA) reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Lombard Odier Asset Management (USA) sold 651 Vertex Pharmaceuticals shares in Q4 2025, an estimated $255K.
  • Lombard Odier Asset Management (USA) first reported a position in Vertex Pharmaceuticals in Q1 2020 and held it in 5 quarters.
  • Lombard Odier Asset Management (USA)'s Vertex Pharmaceuticals position peaked at $7.56M in Q3 2021.
  • 1,668 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Lombard Odier Asset Management (USA)'s 13F filing for Q4 2025, filed 17 Feb 2026.